Astrazeneca (AZN) EBITDA (2016 - 2026)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Astrazeneca has reported EBITDA over the past 16 years, most recently at $2.7 billion for Q1 2026.

• For Q1 2026, EBITDA fell 32.6% year-over-year to $2.7 billion; the TTM value through Mar 2026 reached $11.6 billion, up 36.71%, while the annual FY2025 figure was $12.9 billion, 107.27% up from the prior year.
• EBITDA for Q1 2026 was $2.7 billion at Astrazeneca, down from $2.8 billion in the prior quarter.
• Over five years, EBITDA peaked at $4.0 billion in Q1 2025 and troughed at -$372.0 million in Q2 2022.
• A 5-year average of $1.8 billion and a median of $1.8 billion in 2023 define the central range for EBITDA.
• Biggest five-year swings in EBITDA: crashed 131.23% in 2022 and later skyrocketed 2603.6% in 2025.
• Year by year, EBITDA stood at $1.7 billion in 2022, then increased by 3.91% to $1.8 billion in 2023, then tumbled by 106.24% to -$111.0 million in 2024, then skyrocketed by 2603.6% to $2.8 billion in 2025, then fell by 2.41% to $2.7 billion in 2026.
• Business Quant data shows EBITDA for AZN at $2.7 billion in Q1 2026, $2.8 billion in Q4 2025, and $2.6 billion in Q3 2025.

Peer Comparison